Impact of adalimumab on work participation in rheumatoid arthritis: Comparison of an open-label extension study and a registry-based control group

Annals of the Rheumatic Diseases

Volumn 68, Issue 6, 2009, Pages 930-937

  Halpern, M T ^a   Cifaldi, M A ^b   Kvien, T K ^c,d  

^a EMORY UNIVERSITY   (United States)

^b ABBOTT LABORATORIES   (United States)

^c DIAKONHJEMMET HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG;

ADULT; ARTICLE; DRUG EFFICACY; DRUG WITHDRAWAL; EMPLOYMENT STATUS; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; WORK;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; CLINICAL TRIALS AS TOPIC; DISABILITY EVALUATION; EMPLOYMENT; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REGISTRIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; WORK SCHEDULE TOLERANCE;

EID: 67449132626     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.092734     Document Type: Article

References (60)

1. Hanova P, Pavelka K, Dostal C, Holcatova I, Pikhart H. Epidemiology of rheumatoid arthritis, juvenile idiopathic arthritis and gout in two regions of the Czech Republic in a descriptive population-based survey in 2002-2003. Clin Exp Rheumatol 2006;24:499-507. (Pubitemid 44913611)
2. Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res 2002;4(Suppl 3):S265-72.
3. Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford) 2002;41:793-800. (Pubitemid 34822963)
4. Yelin E, Callahan LF, for the National Arthritis Data Work Group. The economic cost and social psychological impact of musculoskeletal conditions. Arthritis Rheum 1995;38:1351-1356
5. Choi HK, Hernan MA, Seeger SD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-1177 (Pubitemid 34304256)
6. Maetzel A, Tugwell P, Boers M, Guillemin F, Coyle D, Drummond M, et al. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. J Rheumatol 2003;30:891-896 (Pubitemid 36402796)
7. Pincus T, Callahan LF. The 'side effects' of rheumatoid arthritis: joint destruction, disability, and early mortality. Br J Rheumatol 1993;32(Suppl 1):28-37.
8. Wolfe F, Michaud K, Gefeller O, Choi HK. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 2003;48:1530-1542 (Pubitemid 36682360)
9. Wong JB, Ramey DR, Singh G. Long-term morbidity, mortality and economics of rheumatoid arthritis. Arthritis Rheum 2001;44:2746-2749 (Pubitemid 34016193)
10. Kobelt G, Eberhardt K, Jönsson L, Jönsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999;42:347-356 (Pubitemid 29072853)
11. Leardini G, Salaffi F, Montanelli R, Gerzeli S, Canesi B. A multicenter cost-of-illness study on rheumatoid arthritis in Italy. Clin Exp Rheumatol 2002;20:505-515 (Pubitemid 34846625)
12. Yelin E. The costs of rheumatoid arthritis: absolute, incremental and marginal estimates. J Rheumatol 1996;23(Suppl 44):47-51. (Pubitemid 26094647)
13. Jonsson D, Husberg M. Socioeconomic costs of rheumatic diseases. Implications for technology assessment. Int J Technol Assess Health Care 2000;16:1193-1200
14. Schmidt A, Husberg M, Bernfort L. Socioeconomic costs for rheumatic disease. CMT Rapport 2003:5. Linköping: Centre for Medical Technology Assessment, Linköping University, Sweden [in Swedish].
15. Hallert E, Husberg M, Jonsson D, Skogh T. Rheumatoid arthritis is already expensive during the first year of the disease (the Swedish TIRA project). Rheumatology (Oxford) 2004;43:1374-1382 (Pubitemid 39480923)
16. Hallert E, Husberg M, Skogh T. Costs and course of disease and function in early rheumatoid arthritis: a 3-year follow-up (the Swedish TIRA project). Rheumatology (Oxford) 2006;45:325-331 (Pubitemid 43372849)
17. Clarke AE, Levinton C, Joseph L, Penrod J, Zowall H, Sibley JT, et al. Predicting the short term direct medical costs incurred by patients with rheumatoid arthritis. J Rheumatol 1999;26:1068-1075 (Pubitemid 29215070)
18. Lubeck DP, Spitz PW, Fries JF, Wolfe F, Mitchell DM, Roth SH. A multicenter study of annual health service utilization and costs in rheumatoid arthritis. Arthritis Rheum 1986;29:488-493 (Pubitemid 16118697)
19. Merkesdal S, Ruof J, Schoffski O, Bernitt K, Zeidler H, Mau W. Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum 2001;44:528-534 (Pubitemid 32234610)
20. Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 1999;42:1209-1218
21. Odegard S, Finset A, Kvien TK, Mowinckel P, Uhlig T. Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7-year study from the Oslo RA register. Scand J Rheumatol 2005;34:441-447 (Pubitemid 43062198)
22. Li X, Gignac MA, Anis AH. The indirect costs of arthritis resulting from unemployment, reduced performance, and occupational changes while at work. Med Care 2006;44:304-310
23. Kavanaugh A, Han C, Bala M. Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis. J Rheumatol 2004;31:849-855 (Pubitemid 38585806)
24. Kremer JM. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med 2001;138:695-706. (Pubitemid 32322246)
25. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-2204 (Pubitemid 29009378)
26. Maini R, St. Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:932-939
27. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-147 (Pubitemid 27306284)
28. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45. (Pubitemid 36091645)
29. Burton W, Morrison A, Maclean R, Ruderman E. Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med (Lond) 2006;56:18-27. (Pubitemid 43103362)
30. Yelin E, Trupin L, Katz P, Lubeck D, Rush S, Wanke L. Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis Rheum 2003;48:3046-3054 (Pubitemid 37409314)
31. Mittendorf T, Dietz BM, von der Schulenburg JM, Benter U, Cifaldi M, Sterz R. Adalimumab-treated patients with long-standing rheumatoid arthritis (RA) decrease their resource utilization during the course of long-term treatment. Rheumatology 2007;46(Suppl 1):i103.
32. den Broeder AA, van de Putte LBA, Rau R, Schattenkirchner M, van Riel P, Sander O, et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-α antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 2002:29:2288-2298
33. Rau R, Sander O, den Broeder A, Van Riel P, van der Putte L, Kruger K, et al. Long term efficacy and tolerability of multiple IV doses of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 1998;41(Suppl):S55 (abstract 137).
34. Schattenkirchner M, Kruger K, Sander O, Rau R, Kroot E-J, van Riel PLCM, et al. Efficacy and tolerability of weekly subcutaneous injections of the fully human anti- TNF-antibody D2E7 in patients with rheumatoid arthritis - results of a Phase I study. Arthritis Rheum 1998;41(Suppl):S57.
35. van de Putte LBA, Rau R, Breedveld FC, Kalden JR, Malaise MG, van Riel PLCM, et al. Efficacy and safety of the fully human anti-tumour necrosis factor monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study.Ann Rheum Dis 2003;62:1168-1177
36. Rau R, Simianer S, van Riel PLCM, van de Putte LBA, Krüger K, Schattenkirchner M, et al. Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate. Scand J Rheumatol 2004;33:145-153 (Pubitemid 38748100)
37. van de Putte LBA, Atkins C, Malaise M, Sany J, Russell AS, van Riel PLCM, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed.Ann Rheum Dis 2004;63:508-516
38. Kvien TK, Heiberg MS, Lie E, Mikkelsen K, Nordvåg BY, Rødevand E. A Norwegian DMARD register: Prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. Clin Exp Rheumatol 2005;23(Suppl 39):188-194 (Pubitemid 46657527)
39. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324
40. van Gestel AM, Prevoo MLL, Van't Hof MA, Van Rijswijk MH, Van de Putte LBA, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Arthritis Rheum 1996;39:34-40. (Pubitemid 126575924)
41. van Gestel AM, van Riel PL. Evaluation of early rheumatoid arthritis disease activity and outcome. Baillieres Clin Rheumatol 1997;11:49-63. (Pubitemid 27136192)
42. Valesini G, Iannuccelli C, Marocchi E, Pascoli L, Scalzi V, Di Franco M. Biological and clinical effects of anti-TNF alpha treatment. Autoimmun Rev 2007;7:35-41. (Pubitemid 47633389)
43. Wong M, Ziring D, Korin Y, Desai S, Kim S, Lin J, et al. TNF alpha blockade in human diseases: mechanisms and future directions. Clin Immunol 2008;126:121-136
44. Haraoui B. The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis. J Rheumatol Suppl 2005;72:46-47 (Pubitemid 40075955)
45. Voulgari PV, Drosos AA. Adalimumab for rheumatoid arthritis. Expert Opin Biol Ther 2006;6:1349-1360 (Pubitemid 44875688)
46. Odegard S, Landewé R, van der Heijde D, Kvien TK, Mowinckel P, Uhlig T. Association of early radiographic damage with impaired physical function in rheumatoid arthritis: a ten-year, longitudinal observational study in 238 patients. Arthritis Rheum 2006;54:68-75. (Pubitemid 43122188)
47. van Vollenhoven RF, Ray S, Bojke C, Cifaldi MA, Weisman M. Impact of adalimumab (HUMIRA®) combination therapy on expected resource use by patients with early rheumatoid arthritis: results from a companion study to PREMIER [abstract]. Ann Rheum Dis 2008;67(Suppl II):650 (abstract AB1079).
48. Chant C, Wilson G, Friedrich JO. Validation of an insulin infusion nomogram for intensive glucose control in critically ill patients. Pharmacotherapy 2005;25:352-359 (Pubitemid 40300322)
49. Fisher DA, Trimble S, Clapp B, Dorsett K. Effect of a patient management system on outcomes of total hip and knee arthroplasty. Clin Orthop Relat Res 1997;345:155-160 (Pubitemid 28007498)
50. Ingle GR, Moudgil A, Vo A, Jordan SC. Cyclosporine-sparing effects of daclizumab in renal allograft recipients. Am J Health-System Pharm 2005;62:391-396 (Pubitemid 40394618)
51. Tegtmeyer FK, Moller J, Richter A, Wilken B, Fischer T. Plasma concentration of elastase-alpha 1-proteinase inhibitor complex in surfactant-treated preterm neonates with respiratory distress syndrome. Eur Respir J 1994;7:260-264 (Pubitemid 2044308)
52. Wolfe F, Michaud K. Towards an epidemiology of rheumatoid arthritis outcome with respect to treatment: randomized controlled trials overestimate treatment response and effectiveness. Rheumatology (Oxford) 2005;44(Suppl 4):iv18-iv22. (Pubitemid 41724324)
53. van der Heijde D, Han C, DeVlam K, Burmester G, van den Bosch F, Williamson P, et al. Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial. Arthritis Rheum 2006;55:569-574 (Pubitemid 44289876)
54. Smolen JS, Han C, van der Heijde D, Emery P, Bathon JM, Keystone E, et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum 2006;54:716-722
55. Puolakka K, Kautiainen H, Mottonen T, Hannonen P, Korpela M, Julkunen H, et al. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. Arthritis Rheum 2004;50:55-62. (Pubitemid 38084287)
56. Puolakka K, Kautiainen H, Mottonen T, Hannonen P, Hakala M, Korpela M, et al. Predictors of productivity loss in early rheumatoid arthritis: a 5-year follow-up study. Ann Rheum Dis 2005;64:130-133 (Pubitemid 40075290)
57. Chung DP, Sokka T, Arbogast PG, Pincus T. Work disability in early rheumatoid arthritis: higher rates but better clinical status in Finland compared with the US. Ann Rheum Dis 2006;65:1653-1657 (Pubitemid 44799682)
58. Zandbelt MM, Houbiers JG, van den Hoogen FH, Meijerink J, van Riel PL, in't Hout J, et al. Intranasal administration of recombinant human cartilage glycoprotein-39. A phase I escalating cohort study in patients with rheumatoid arthritis. J Rheumatol 2006;33:1726-1733 (Pubitemid 44373202)
59. Statistics Norway. Focus on wages. http://www.ssb.no/english/subjects/06/ lonn-en/ (accessed 18 Dec 2006).
60. Universal Currency Converter. http://www.oanda.com (accessed 18 Dec 2006).